सत्याधीशसत्याधीश
SatyaDheesh
India's Ground Truth Record
Pull to refresh
VOL. I · EST. 11.2025 
SatyaDheesh
सत्याधीश
India's Ground Truth Record
LIVE

Delhi High Court Rejects Stay on HPV Vaccination Drive

GS2Polity · Governance · IR· Health policy & public health· Prelims·

Why in news

The Delhi High Court refused to stay the HPV vaccination drive after the Centre provided data on low Adverse Events Following Immunization (AEFI) rates.

Background

The Centre reported that out of 56 lakh doses administered, only 120 adverse events were recorded. The AEFI rate was cited at approximately 0.0022%, which is significantly lower than FDA benchmarks.

Facts for Prelims

  • FactAEFI rate for HPV vaccination drive reported at 0.0022%
  • FactTotal doses administered: ~56 lakh
  • S&TGardasil is a vaccine manufactured by Merck used to prevent HPV
  • BodyDelhi High Court: Judicial body overseeing the legality of the vaccination drive

For Mains

Q. Discuss the challenges in balancing public health imperatives with individual safety concerns during large-scale national immunization programs in India.

Dimensions to cover in your answer

  • public health infrastructure
  • data transparency
  • regulatory oversight
  • risk-benefit analysis

Keywords: AEFI · public health · immunization · regulatory compliance · risk assessment

Read the full news →Report a mistake in this noteSource: Indian Express ↗Also: GS3 · Biotechnology & health research

More Social Justice notes

All Social Justice current affairs →

Something wrong, or something missing?

Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.

Report a mistake →Ask for something →thesatyadheesh@gmail.com

This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.